Ashurst joins US and Irish firms as Elan rejects Royalty Pharma bid
A raft of Irish, UK and US firms have won roles on the battle for control of Irish biotechnology company Elan, which yesterday (22 April) rejected a hostile offer by US pharmaceutical investment giant Royalty Pharma. Matheson partners Tim Scanlon, George Brady and Fergus Bolster are leading the Irish advice for Royalty Pharma, which launched […]